Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Erebor Joan Onyebuchi; Agboluaje Elizabeth Oladoyin; Perkins Ava M.; Krishnakumar Megha; Ngwuluka Ndidi

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Advanced Pharmaceutical Bulletin Year:2024 | Volume:14 | Issue:3 Page(s): 558-573

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy

Author(s)

Keywords

Keywords: Cancer therapyQ4

Hybrid nanocarriersQ4

Co-deliveryQ4

Drug deliveryQ4

TargetedQ4

NanoparticlesQ4

Abstract

Hybrid nanocarriers have realized a growing interest in Drug delivery research because of the potential of being able to treat, manage or cure diseases that previously had limited therapy or cure. Cancer is currently considered the second leading cause of death globally. This makes cancer therapy a major focus in terms of the need for efficacious and safe drug formulations that can be used to reduce the rate of morbidity and mortality globally. The major challenge encountered over the years with cancer chemotherapy is the non-selectivity of anticancer drugs, leading to severe adverse effects in patients. Multidrug resistance has also resulted in treatment failure in cancer chemotherapy over the years. Hybrid nanocarriers can be Targeted to the site and offer Co-delivery of two or more chemotherapeutics, thus leading to synergistic or additive results. This makes Hybrid nanocarriers an extremely attractive type of Drug delivery system for cancer therapy. Hybrid nanocarrier systems are also attracting attention as possible non-viral gene vectors that could have a higher level of transfection, and be efficacious, with the added advantage of being safer than viral vectors in clinical settings. An extensive review of various aspects of Hybrid nanocarriers was discussed in this paper. It is envisaged that in the future, metastatic cancers, multi-drug resistant cancers, and low prognosis cancers like pancreatic cancers, will have a lasting solution via hybrid nanocarrier formulations with Targeted Co-delivery of therapeutics.

Cites

No record.

References

No record.

Cite

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops